The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib.
 
Mazyar Shadman
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Cellectar; Epizyme; Genentech; Innate Pharma; Kite, a Gilead company; MorphoSys; Pharmacyclics; Sound Biologics
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); BeiGene (Inst); Bristol-Myers Squibb/Celgene; Celgene (Inst); Genentech (Inst); Merck (Inst); MustangBio (Inst); Pharmacyclics (Inst); Sunesis Pharmaceuticals (Inst); TG Therapeutics (Inst)
 
Jeff Porter Sharman
Employment - US Oncology Network
Stock and Other Ownership Interests - VelosBio
Consulting or Advisory Role - Abbvie; Acerta Pharma/AstraZeneca; Beigene; Bristol-Myers Squibb; Celgene; Genentech; Pfizer; Pharmacyclics; TG Therapeutics
Research Funding - Acerta Pharma (Inst); Celgene (Inst); Genentech (Inst); Gilead Sciences (Inst); Merck (Inst); Pharmacyclics (Inst); Seagen (Inst); Takeda (Inst); TG Therapeutics (Inst)
 
Moshe Y. Levy
Employment - Baylor University Medical Center
Consulting or Advisory Role - BeiGene
Speakers' Bureau - Abbvie; Amgen; AstraZeneca; BeiGene; Bristol-Myers Squibb; Dova Pharmaceuticals; Epizyme; Gilead Sciences; GlaxoSmithKline; Janssen; Jazz Pharmaceuticals; Karyopharm Therapeutics; MorphoSys; Sanofi; Seagen; Takeda
Research Funding - BeiGene
 
Ryan Porter
No Relationships to Disclose
 
Syed Farhan Zafar
Employment - Florida Cancer Specialists
Honoraria - AstraZeneca; Bristol-Myers Squibb; Karyopharm Therapeutics
Research Funding - Sarah Cannon Research Institute
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb
 
John M. Burke
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; AstraZeneca; Bayer; BeiGene; Epizyme; Genentech/Roche; Kura Oncology; Kymera; MorphoSys; Novartis; Seagen; Verastem
Speakers' Bureau - Beigene; Seagen
 
Arvind Chaudhry
Stock and Other Ownership Interests - Novartis
Honoraria - Bayer
Consulting or Advisory Role - Bayer
 
Benjamin Bruce Freeman
No Relationships to Disclose
 
Jamal Ghazi Misleh
No Relationships to Disclose
 
Habte Aragaw Yimer
Employment - Texas Oncology
Stock and Other Ownership Interests - Epizyme; Karyopharm Therapeutics
Consulting or Advisory Role - Amgen; AstraZeneca; Karyopharm Therapeutics
Speakers' Bureau - Amgen; AstraZeneca; BeiGene; Janssen; Karyopharm Therapeutics; Takeda
Research Funding - BeiGene; Janssen
Travel, Accommodations, Expenses - Amgen; AstraZeneca; BeiGene; Janssen; Karyopharm Therapeutics
 
Jennifer L. Cultrera
Employment - Florida Cancer Specialists
Speakers' Bureau - Amgen; Aurobindo; Celgene
Research Funding - Acerta Pharma; AstraZeneca; BeiGene; Bristol-Myers Squibb; EMD Serono; Genentech; Lilly; Merck; Seagen; Takeda
 
Troy H. Guthrie
Employment - GenesisCare
 
Ed Kingsley
No Relationships to Disclose
 
Subramanya S. Rao
No Relationships to Disclose
 
Dih-Yih Chen
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Aileen Cohen
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Shibao Feng
Employment - BeiGene
Stock and Other Ownership Interests - Amgen; Annexon Biosciences; BeiGene; Hutchison China Meditech; Illumina; Nektar
Patents, Royalties, Other Intellectual Property - BeiGene
 
Jane Huang
Employment - BeiGene
Leadership - BeiGene
Stock and Other Ownership Interests - BeiGene
Patents, Royalties, Other Intellectual Property - BeiGene (Inst)
Travel, Accommodations, Expenses - BeiGene (Inst)
 
Ian Flinn
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); BeiGene (Inst); Genentech (Inst); Gilead Sciences (Inst); Great Point Partners (Inst); Iksuda Therapeutics (Inst); Janssen (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); MorphoSys (Inst); Novartis (Inst); Nurix (Inst); Pharmacyclics (Inst); Roche (Inst); Seagen (Inst); Shanghai Yingli Pharmaceuticals (Inst); Takeda (Inst); TG Therapeutics (Inst); Unum Therapeutics (Inst); Verastem (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Agios (Inst); ArQule (Inst); AstraZeneca (Inst); BeiGene (Inst); Calithera Biosciences (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Curis (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); IGM Biosciences (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); Juno Therapeutics (Inst); Karyopharm Therapeutics (Inst); Kite, a Gilead company (Inst); Loxo (Inst); Merck (Inst); MorphoSys (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Portola Pharmaceuticals (Inst); Rhizen Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); Takeda (Inst); Teva (Inst); TG Therapeutics (Inst); Triact Therapeutics (Inst); Trillium Therapeutics (Inst); Unum Therapeutics (Inst); Verastem (Inst)